On July 30, WUXI XDC fell 3.21% in regular trading, trading at 51.3 HKD/share, with turnover of 63.05 million HKD.

On the news front, Nomura published a report cutting WUXI XDC's target price from 87.73 HKD to 82.6 HKD while maintaining a \"Buy\" rating. Notably, the bank slashed its fiscal year earnings forecast by 22.3%, citing negative foreign exchange impact and higher management expenses related to the acquisition of Dongzhao Pharma. Nomura expects first-half revenue of 3.8 billion yuan, up 41.2% year-on-year, driven by organic business growth and Dongzhao's contribution of 225 million yuan since consolidation in April. However, operating margin is estimated to decline 1.1 percentage points to 27.4% due to M&A-related costs.

Within the Life Sciences Tools and Services sector, the overall sector came under pressure. Among individual stocks, WUXI BIO down 2.54%, INSILICO down 2.07%, XTALPI down 1.47%, WUXI APPTEC down 1.45%, GENSCRIPT BIO down 1.03%.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)